APLT
Applied Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Stock Price Surged Significantly
MACD Golden Cross
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
RSI Oversold
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APLT
Applied Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets
Pharmaceutical
01/20/2016
05/14/2019
NASDAQ Stock Exchange
35
12-31
Common stock
545 Fifth Avenue, Suite 1400, New York, NY 10017
--
Applied Therapeutics, Inc., was incorporated in Delaware on January 20, 2016 and is headquartered in New York. The company is a clinical-stage biopharmaceutical company that develops a portfolio of new product candidates targeting potent molecular targets with unmet medical needs. The company's approach to drug development utilizes recent technological advances to design improved drugs, utilizes early use of biomarkers to confirm biological activity, and focuses on shortened regulatory pathways. The company's first molecular target is aldose reductase, or AR, an enzyme that converts glucose to sorbitol under oxidative stress conditions and is involved in a variety of diseases. The company's AR inhibitor or ARI program currently includes three small molecules, all of which are designed to be effective selective ARI and designed to have unique tissue permeability characteristics to target different disease states, including diabetic complications, heart disease and rare pediatric metabolic diseases. The company's ARI program application strategy, the company has also developed a program for the selective inhibition of phosphatidylinositol 3- kinase, or PI3K subunit, which has led to early oncology therapy.
Company Financials
EPS
APLT has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.14, beating expectations. The chart below visualizes how APLT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
APLT has released its 2025 Q3 earnings report, with revenue of 1.00M, reflecting a YoY change of 719.67%, and net profit of -18.99M, showing a YoY change of 72.31%. The Sankey diagram below clearly presents APLT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
